In our last review of Bristol-Myers Squibb (BMY) on March 9 after a quantitative downgrade from TheStreet's Quant Ratings service, we wrote that, "The downgrade to hold by our quantitative service does not help our cause. At current levels BMY is sort-of in no man's land - not bullish and not bearish. Traders who are flat should wait for a close above $68 to go long, and traders who are still long and can risk a wider stop could hold."
More from Stocks
IBM has been frustrating as a turnaround name, but it's now pressing the right buttons -- and has a high yield.
The intense rally in NUE makes it look like a cloud or tech name.
Just look at Snowflake, the ARKK and compare to the S&P 500 and Dow.
A trader needs to go where they have comfort, especially if buying shares.